Aoki Y, Yarchoan R, Wyvill K, Okamoto S, Little R F, Tosato G
Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Blood. 2001 Apr 1;97(7):2173-6. doi: 10.1182/blood.v97.7.2173.
Expression of a viral interleukin-6 (vIL-6) has been detected in certain Kaposi sarcoma (KS)--associated herpesvirus positive (KSHV(+)) lesions. The release of vIL-6 systemically and its contribution to the pathogenesis of HIV-related malignancies was studied. Serum vIL-6 was detected in 13 (38.2%) of 34 HIV(+) patients with KS, in 6 (85.7%) of 7 HIV(+) patients with primary effusion lymphoma (PEL) and/or multicentric Castleman disease (MCD), and in 18 (60.0%) of 30 HIV(+), mostly homosexual, individuals without KS, MCD, or PEL. By contrast, serum vIL-6 was detected in only 3 (23.1%) of 13 patients with classic KS, 1 (2.5%) of 40 blood donors from the United States, and 4 (19.0%) of 21 blood donors from Italy. Circulating vIL-6 levels were associated with HIV(+) status (P <.0001). However, within the HIV(+) cohort, serum vIL-6 levels were not associated with the occurrence of KSHV-associated malignancies (P =.43). (Blood. 2001;97:2173-2176)
在某些卡波西肉瘤（KS）相关疱疹病毒阳性（KSHV(+)）病变中已检测到病毒白细胞介素-6（vIL-6）的表达。对vIL-6的全身释放及其对HIV相关恶性肿瘤发病机制的作用进行了研究。在34例患有KS的HIV(+)患者中，有13例（38.2%）检测到血清vIL-6；在7例患有原发性渗出性淋巴瘤（PEL）和/或多中心Castleman病（MCD）的HIV(+)患者中，有6例（85.7%）检测到血清vIL-6；在30例大多为同性恋的无KS、MCD或PEL的HIV(+)个体中，有18例（60.0%）检测到血清vIL-6。相比之下，在13例经典KS患者中，仅3例（23.1%）检测到血清vIL-6；在美国的40名献血者中，1例（2.5%）检测到血清vIL-6；在意大利的21名献血者中，4例（19.0%）检测到血清vIL-6。循环vIL-6水平与HIV(+)状态相关（P<.0001）。然而，在HIV(+)队列中，血清vIL-6水平与KSHV相关恶性肿瘤的发生无关（P = 0.43）。（《血液》。2001年；97:2173 - 2176）
